Kühne Holding AG has entered into a definitive agreement to acquire pharma contract development and manufacturing organisation Aenova Group from leading international investment firm BC Partners.
FUJIFILM Corporation have announced an investment of $1.2 billion in its Large-Scale Cell Culture CDMO Business to further expand the planned FUJIFILM Diosynth Biotechnologies end-to-end bio-manufacturing facility in Holly Springs, North Carolina.
Following the DVPs first 10 investments, Emma Palmer Foster, Director of Discovery Park Ventures, and Martino Picardo, Director of DPV and Chairman of Discovery Park, share their learnings and insights into life science investing.
BBI Solutions OEM Limited (BBI) has announced the successful closing of the acquisition of IBEX Technologies Inc. (IBEX), a leading developer and manufacturer of high-precision enzymes and diagnostic solutions located in Montréal, Québec.
Bespak have announced the completion of the transaction to separate Recipharm’s former Advanced Delivery Systems Business Unit from the Recipharm Group to form a new standalone company.
Blackstone have announced a new collaboration with Moderna through a development and commercialisation funding agreement where funds managed by Blackstone Life Sciences and will provide up to $750 million to fund Moderna’s influenza program.
Biocon Biologics Limited have announced a long -term commercial collaboration with Eris Lifesciences to expand patient access to its portfolio of Metabolics, Oncology, and Critical Care products in India.
Speaking at an event in Edinburgh, Chris Dougray, Head of Development at CBRE Scotland, and Chris Williams, CBRE’s Head of Life Sciences, joined forces to examine the burgeoning sector’s place in Scotland.
Sandoz have entered into a settlement agreement with the class of direct purchaser plaintiffs in the multidistrict litigation entitled In re Generic Pharmaceuticals Pricing Antitrust Litigation.
Bristol Myers Squibb have announced a $400 million investment in their Dublin 15 Cruiserath Campus towards the build and design of a Sterile Drug Product facility.
Takeda and Biological E. Limited, an India-based vaccines and pharmaceutical company, have announced a strategic partnership to accelerate access to QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials.
